Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 71 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H1 2015’, provides an overview of the Primary Progressive Multiple Sclerosis (PPMS)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Primary Progressive Multiple Sclerosis (PPMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Primary Progressive Multiple Sclerosis (PPMS) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Primary Progressive Multiple Sclerosis (PPMS)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Primary Progressive Multiple Sclerosis (PPMS) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Primary Progressive Multiple Sclerosis (PPMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Primary Progressive Multiple Sclerosis (PPMS) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Primary Progressive Multiple Sclerosis (PPMS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Primary Progressive Multiple Sclerosis (PPMS) Overview 6
Therapeutics Development 7
Pipeline Products for Primary Progressive Multiple Sclerosis (PPMS) - Overview 7
Pipeline Products for Primary Progressive Multiple Sclerosis (PPMS) - Comparative Analysis 8
Primary Progressive Multiple Sclerosis (PPMS) - Therapeutics under Development by Companies 9
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Primary Progressive Multiple Sclerosis (PPMS) - Products under Development by Companies 13
Primary Progressive Multiple Sclerosis (PPMS) - Companies Involved in Therapeutics Development 14
AB Science 14
Genzyme Corporation 15
Glialogix, Inc. 16
Innate Immunotherapeutics Limited 17
Kyorin Pharmaceutical Co., Ltd. 18
MedDay 19
Santhera Pharmaceuticals Holding AG 20
Teva Pharmaceutical Industries Limited 21
Primary Progressive Multiple Sclerosis (PPMS) - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
GLX-1112 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
GZ-402668 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ibudilast - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
idebenone - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
laquinimod sodium - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
masitinib - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
MD-1003 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MIS-416 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecules for Multiple Sclerosis - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Primary Progressive Multiple Sclerosis (PPMS) - Recent Pipeline Updates 49
Primary Progressive Multiple Sclerosis (PPMS) - Discontinued Products 68
Primary Progressive Multiple Sclerosis (PPMS) - Product Development Milestones 69
Featured News & Press Releases 69
Mar 04, 2015: MedDay to present Pivotal Phase III data in Progressive Multiple Sclerosis at AAN Annual Meeting 69
Feb 01, 2015: MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at AAN 67th Annual Meeting in Washington, DC 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71

List of Tables

Number of Products under Development for Primary Progressive Multiple Sclerosis (PPMS), H1 2015 7
Number of Products under Development for Primary Progressive Multiple Sclerosis (PPMS) - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by AB Science, H1 2015 14
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Genzyme Corporation, H1 2015 15
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Glialogix, Inc., H1 2015 16
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Innate Immunotherapeutics Limited, H1 2015 17
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 18
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by MedDay, H1 2015 19
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2015 20
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 21
Assessment by Monotherapy Products, H1 2015 22
Number of Products by Stage and Target, H1 2015 24
Number of Products by Stage and Mechanism of Action, H1 2015 26
Number of Products by Stage and Route of Administration, H1 2015 28
Number of Products by Stage and Molecule Type, H1 2015 30
Primary Progressive Multiple Sclerosis (PPMS) Therapeutics - Recent Pipeline Updates, H1 2015 49
Primary Progressive Multiple Sclerosis (PPMS) - Discontinued Products, H1 2015 68